Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Hormone and Metabolic Research

Volumn 47, Issue 11, 2015, Pages 805-812

  Liang, W ^a   Gao, L ^a   Li, N ^a   Wang, B ^b   Wang, L ^a   Wang, Y ^b   Yang, H ^a   You, L ^b   Hou, J ^a   Chen, S ^a   Zhu, H ^a   Jiang, Y ^b   Pan, H ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

bromocriptine QR; efficacy; safety; type 2 diabetes

Indexed keywords

BROMOCRIPTINE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DEATH; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFECTION; META ANALYSIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; TREATMENT OUTCOME;

EID: 84942986312     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1559684     Document Type: Review

References (49)

1. Meier A. H., Cincotta A. H. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev: 1996; 4 464 487
2. Scranton R., Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother: 2010; 11 269 279
3. Kalra S., Kalra B., Agrawal N., Kumar S. Dopamine: The Forgotten Felon in Type 2 Diabetes. Rec Pat Endocr Metab Immune Drug Discov: 2011; 5 61 65
4. Luo S., Luo J., Cincotta A. H. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology: 1999; 70 460 465
5. Reynolds G. P., Kirk S. L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Therap: 2010; 125 169 179
6. García-Tornadú I., Ornstein A. M., Chamson-Reig A., Wheeler M. B., Hill D. J., Arany E., Rubinstein M., Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology: 2010; 151 1441 1450
7. Defronzo R. A. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care: 2011; 34 789 794
8. Schwartz S. L. Bromocriptine (Ergoset (R)) improves glycemic control in type 2 diabetics on insulin. Diabetes: 1999; 48 A99 A99
9. Ezrokhi M., Luo S., Cincotta J., Cincotta A. H. Timed dopamine agonist therapy induces a postprandial-selective insulin sensitivity. Diabetologia: 2008; 51 S276 S276
10. Bell D. S. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgrad Med: 2012; 124 121 135
11. Via M. A., Chandra H., Araki T., Potenza M. V., Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndrome Obes: 2010; 3 43 48
12. Moher D., Liberati A., Tetzlaff J., Altman D. G. Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol: 2009; 62 1006 1012
13. Goldstein D. E., Little R. R., Lorenz R. A., Malone J. I., Nathan D., Peterson C. M., Sacks D. B. Tests of glycemia in diabetes. Diabetes Care: 2004; 27 1761 1773
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials: 1986; 7 177 188
15. Higgins J. P., Thompson S. G. Quantifying heterogeneity in a meta-analysis. Statistics Med: 2002; 21 1539 1558
16. Ghosh A., Sengupta N., Sahana P., Giri D., Sengupta P., Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial. Indian J Pharmacol: 2014; 46 24 28
17. Vinik A. I., Cincotta A. H., Scranton R. E., Bohannon N., Ezrokhi M., Gaziano J. M. Effect of Bromocriptine-Qr on Glycemic Control in Subjects with Uncontrolled Hyperglycemia on One or Two Oral Anti-Diabetes Agents. Endocr Pract: 2012; 18 931 943
18. Ramteke K. B., Ramanand S. J., Ramanand J. B., Jain S. S., Raparti G. T., Patwardhan M. H., Murthy M., Ghanghas R. G. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab: 2011; 15 S33 S39
19. Florez H., Scranton R., Farwell W. R., DeFronzo R. A., Ezrokhi M., Gaziano J. M., Cincotta A. H. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J. Diabetes Metab: 2011; 2 142
20. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V., Pipek R., Iozzo P., Lancaster J. L., Cincotta A. H., DeFronzo R. A. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care: 2000; 23 1154 1161
21. Cincotta A. H., Meier A. H., Cincotta M. Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs: 1999; 8 1683 1707
22. Scranton R., Erzoki M., Farwell W., Gaziano J. M., Cincotta A. Quick release bromocriptine (Cycloset™) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure. Canad J Diabetes: 2009; 33 235
23. Gaziano J. M., Cincotta A. H., Vinik A., Blonde L., Bohannon N., Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc: 2012; 1 e002279
24. Gaziano J. M., Cincotta A. H., O'Connor C. M., Ezrokhi M., Rutty D., Ma Z. J., Scranton R. E. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care: 2010; 33 1503 1508
25. Bell D. S. Why does quick-release bromocriptine decrease cardiac events? Diabetes Obes Metab: 2011; 13 880 884
26. Luo S. Q., Meier A. H., Cincotta A. H. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology: 1998; 68 1 10
27. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem: 2005; 280 36824 36832
28. Maffei A., Segal A. M., Alvarez-Perez J. C., Garcia-Ocana A., Harris P. E. Anti-incretin, Anti-proliferative Action of Dopamine on beta-Cells. Mol Endocrinol: 2015; 29 542 557
29. Roe E. D., Chamarthi B., Raskin P. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study. J Diabetes Res: 2015; 2015 7
30. Ezrokhi M., Luo S., Trubitsyna Y., Cincotta A. H. Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic vs. euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer. J Diabetes Metab: 2012; S2 10.4172/2155-6156.s2-007
31. Ezrokhi M., Luo S., Trubitsyna Y., Cincotta A. H. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr: 2014; 6 104: 10.1186/1758-5996-1186-1104. eCollection 2014
32. Kamath V., Jones C. N., Yip J. C., Varasteh B. B., Cincotta A. H., Reaven G. M., Chen Y. D. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care: 1997; 20 1697 1701
33. Bloomgarden Z. T., Einhorn D. Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol: 2012; 3
34. Goetz C. G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord: 2005; 20 523 539
35. Korczyn A. D., Brooks D. J., Brunt E. R., Poewe W. H., Rascol O., Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disord: 1998; 13 46 51
36. Mizuno Y., Yanagisawa N., Kuno S., Yamamoto M., Hasegawa K., Origasa H., Kowa H. Japanese Pramipexole Study G Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord: 2003; 18 1149 1156
37. Danaei G., Finucane M. M., Lu Y., Singh G. M., Cowan M. J., Paciorek C. J., Lin J. K., Farzadfar F., Khang Y-H, Stevens G. A. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2· 7 million participants. Lancet: 2011; 378 31 40
38. Kaye S. B., Shaw K. M., Ross E. J. Letter: Bromocriptine and hypertension. Lancet: 1976; 1 1176 1177
39. Lokhandwala M. F., Tadepalli A. S., Jandhyala B. S. Cardiovascular actions of bromocriptine: evidence for a neurogenic mechanism. J Pharmacol Exp Therap: 1979; 211 620 625
40. McDonald M. D., Daniel E., Lam M. D., Raymond W. Domperidone for Drug-Induced Orthostatic Hypotension - A Review. Jefferson J Psychiatry: 2011; 10 5
41. Senard J. M., Rai S., Lapeyre-Mestre M., Brefel C., Rascol O., Rascol A., Montastruc J. L. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry: 1997; 63 584 589
42. Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord: 2009; 24 129 133
43. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol: 2007; 6 826 829
44. Kim J. Y., Chung E. J., Park S. W., Lee W. Y. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord: 2006; 21 1261 1264
45. Tan L. C., Ng K. K., Au W. L., Lee R. K., Chan Y. H., Tan N. C. Bromocriptine use and the risk of valvular heart disease. Mov Disord: 2009; 24 344 349
46. Halperin I., Aller J., Varela C., Mora M., Abad A., Doltra A., Santos A. E., Batista E., García-Pavía P., Sitges M., Mirelis J. G., Lucas T., Puig-Domingo M. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol: 2012; 77 275 280
47. Elenkova A., Shabani R., Kalinov K., Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol: 2012; 167 17 25
48. Boguszewski C. L., dos Santos C. M., Sakamoto K. S., Marini L. C., de Souza A. M., Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary: 2012; 15 44 49
49. Drake W. M., Stiles C. E., Howlett T. A., Toogood A. A., Bevan J. S., Steeds R. P. UK Dopamine Agonist Valvulopathy Group A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab: 2014; 99 90 96